感控防护产品

Search documents
振德医疗(603301)10月10日主力资金净买入4159.07万元
Sou Hu Cai Jing· 2025-10-11 00:20
证券之星消息,截至2025年10月10日收盘,振德医疗(603301)报收于56.46元,上涨9.99%,换手率 8.05%,成交量21.45万手,成交额11.95亿元。 10月10日的资金流向数据方面,主力资金净流入4159.07万元,占总成交额3.48%,游资资金净流出 6417.3万元,占总成交额5.37%,散户资金净流入2258.23万元,占总成交额1.89%。 近5日资金流向一览见下表: | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-10 | 56.46 | 9.99% | 4159.07万 | 3.48% | -6417.30万 | -5.37% | 2258.23万 | - 1.89% | | 2025-10-09 | | 51.33 10.01% | 8818.91万 | 21.21% | -964.82万 | -2.32% | -7854.09万 | -18.89% | | 2025-0 ...
振德医疗(603301)8月6日主力资金净卖出589.22万元
Sou Hu Cai Jing· 2025-08-07 00:33
Core Viewpoint - The stock of Zhendemedical (603301) has shown a decline in price and mixed capital flow, indicating potential volatility in the market [1][2]. Financial Performance - As of August 6, 2025, Zhendemedical's stock closed at 22.08 yuan, down 1.3% with a trading volume of 27,700 hands and a transaction amount of 61.39 million yuan [1]. - The company reported a main revenue of 992 million yuan for Q1 2025, a year-on-year increase of 2.87%, while the net profit attributable to shareholders was 51.24 million yuan, a decrease of 30.19% year-on-year [4]. - The company's gross profit margin stands at 34.28%, which is significantly lower than the industry average of 51.31% [4]. Capital Flow Analysis - On August 6, 2025, the net outflow of main funds was 5.89 million yuan, accounting for 9.6% of the total transaction amount, while retail investors saw a net inflow of 7.72 million yuan, representing 12.57% of the total [1]. - Over the past five days, the financing balance has increased, with a net financing purchase of 2.25 million yuan on August 6, 2025, contributing to a cumulative net purchase of 14.04 million yuan over three days [2]. Industry Comparison - Zhendemedical's total market value is 5.883 billion yuan, which is below the industry average of 11.525 billion yuan, ranking 59th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 28.7, significantly lower than the industry average of 61.65, indicating a potentially undervalued stock [4]. Institutional Ratings - In the last 90 days, two institutions have rated Zhendemedical with a "buy" recommendation, and the average target price set by institutions is 27.13 yuan [5].
振德医疗收盘上涨1.07%,滚动市盈率26.89倍,总市值55.21亿元
Sou Hu Cai Jing· 2025-04-14 11:46
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhend Medical, which closed at 20.72 yuan with a PE ratio of 26.89 times, significantly lower than the industry average of 45.71 times [1][2] - Zhend Medical's total market capitalization is reported at 5.521 billion yuan, ranking 66th in the medical device industry based on PE ratio [1][2] - As of the third quarter of 2024, 181 institutions hold shares in Zhend Medical, with a total holding of 20.3871 million shares valued at 448 million yuan [1] Group 2 - The main business of Zhend Medical includes the production, research, and sales of medical dressings, with key products in wound care, surgical infection control, and pressure treatment [1] - The latest financial results for the third quarter of 2024 show Zhend Medical achieved operating revenue of 3.125 billion yuan, a year-on-year decrease of 2.61%, while net profit was 307 million yuan, an increase of 2.31%, with a gross profit margin of 34.84% [1]